Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease

Bezzio, C.; Franchellucci, G.; Savarino, E. V.; Mastronardi, M.; Caprioli, F. A.; Bodini, G.; Variola, A.; Scaldaferri, F.; Furfaro, F.; Calabrese, E.; Principi, M. B.; Biscaglia, G.; Marzo, M.; Michielan, A.; Cavalli, C.; Aratari, A.; Campigotto, M.; Ceccarelli, L.; Cappello, M.; Saibeni, S.; Balestrieri, P.; Soriano, A.; Casini, V.; Bertani, L.; Barberio, B.; Conforti, F. S.; Danese, S.; Armuzzi, A.

doi:10.1093/crocol/otae060

Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with diffcult-to-treat CD being cared for at clinical centers across Italy.

Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease / Bezzio, C.; Franchellucci, G.; Savarino, E. V.; Mastronardi, M.; Caprioli, F. A.; Bodini, G.; Variola, A.; Scaldaferri, F.; Furfaro, F.; Calabrese, E.; Principi, M. B.; Biscaglia, G.; Marzo, M.; Michielan, A.; Cavalli, C.; Aratari, A.; Campigotto, M.; Ceccarelli, L.; Cappello, M.; Saibeni, S.; Balestrieri, P.; Soriano, A.; Casini, V.; Bertani, L.; Barberio, B.; Conforti, F. S.; Danese, S.; Armuzzi, A.. - In: CROHN’S & COLITIS 360. - ISSN 2631-827X. - 6:4(2024). [10.1093/crocol/otae060]